Current/ Expected Orderbook/ Pending Orders?

Fenesta Building System has shown strong accretion in order booking as mentioned on page 7. The business is expanding across geographies and SKUs despite the first quarter slowdown due to elections. No specific numeric value for the current or expected order book or pending orders is disclosed in the transcript. The general tone indicates a healthy pipeline of orders supporting growth momentum in the business segment.

Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. There is no specific discussion regarding new debt issuances or equity raises during the call or in the management comments. The company highlights a strong balance sheet with net debt of Rs. 1,459 crore as of June 30, 2024, and healthy cash flows. Management focuses on organic growth through capacity addition, technology, and new products without referring to external fundraising. They continue to evaluate adjacencies and growth opportunities but have not disclosed any plans for raising funds via debt o

Any current/future capex/capital investment/strategic investment?

Commissioned 850 TPD caustic capacity in May 2024; capacity ramp-up will be gradual due to market oversupply. 120 MW captive power plant commissioned in June 2024, improving cost efficiency. Hydrogen peroxide plant started trial runs; expected to be commissioned in Q2 FY25. Epichlorohydrin plant trials to start in Q2 FY25; commercial production expected early Q3 FY25. Actively working on starting activities on epoxy and other chlorine downstream products; board evaluation ongoing. Evaluating additional chlorine downstream opportunities to increase captive chlorine consumption beyond current ~5

Future growth expectations in sales/revenue/volumes?

Chemicals Business: Optimistic about medium-term growth with capacity additions being absorbed comfortably due to steady demand across end-user industries (textiles, paper, alumina, etc.). Caustic Soda: Expect steady volume growth domestically and in exports; aiming for significant capacity utilization by end of FY25 and optimal utilization by next year. Chlorine Derivatives: Evaluating new downstream products to increase in-house consumption and expand revenue streams over next 2-4 years. Epichlorohydrin: Ramp-up post-commissioning expected in Q3-Q4 FY25 with most revenue benefits antic

Future growth expectations in earnings/operating earnings/profits/EPS?

Steady growth is expected driven by capacity expansion, capability enhancement, technology, new products, and value addition. Chemicals and Vinyl businesses show improvement due to supportive cost environment and capacity additions, like the 850 TPD caustic capacity commissioned in May 2024. Capacity ramp-up for new chemical capacities (caustic soda, epichlorohydrin, hydrogen peroxide) will be gradual due to short-term oversupply but positive medium-term outlook. SFS (Shriram Farm Solutions) and Fenesta Building Systems businesses are growing and delivering consistent performance. Energy cost

DCM Shriram LtdQ1 FY25Diversified

DCM Shriram Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,002.05P/E: 11.4Market Cap: ₹15.6K CrSector: Diversified

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Chemicals Business: Optimistic about medium-term growth with capacity additions being absorbed comfortably due to steady demand across end-user industries (textiles, paper, alumina, etc.).
Caustic Soda: Expect steady volume growth domestically and in exports; aiming for significant capacity utilization by end of FY25 and optimal utilization by next year.
Chlorine Derivatives: Evaluating new downstream products to increase in-house consumption and expand revenue streams over next 2-4 years.
Epichlorohydrin: Ramp-up post-commissioning expected in Q3-Q4 FY25 with most revenue benefits anticipated in next financial year.
Shriram Farm Solutions: Maintaining double-digit topline growth driven by new product launches and R&D initiatives.
Fenesta Building Systems: Continued growth with expanded geographies and product SKUs; short-term impact due to elections expected to normalize.
Sugar & Ethanol: Pressure on margins but expanding ethanol volumes (15% YoY increase), with efforts to meet government blending targets enhancing growth prospects.

Margin guidance

Category 3

Steady growth is expected driven by capacity expansion, capability enhancement, technology, new products, and value addition.
Chemicals and Vinyl businesses show improvement due to supportive cost environment and capacity additions, like the 850 TPD caustic capacity commissioned in May 2024.
Capacity ramp-up for new chemical capacities (caustic soda, epichlorohydrin, hydrogen peroxide) will be gradual due to short-term oversupply but positive medium-term outlook.
SFS (Shriram Farm Solutions) and Fenesta Building Systems businesses are growing and delivering consistent performance.
Energy cost reductions (e.g., renewable captive power plant) enhance cost efficiency.
Some margin pressures remain in sugar and ethanol due to increased costs not fully compensated by prices.
Overall, the company expects sustainable margins supported by operational efficiencies and expanding end-user industries.
Earnings growth will materialize as new plants stabilize, and capacity utilization improves, especially in the second half of FY25 and into FY26.

See what DCM Shriram Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or planned fundraising through debt or equity.
There is no specific discussion regarding new debt issuances or equity raises during the call or in the management comments.
The company highlights a strong balance sheet with net debt of Rs. 1,459 crore as of June 30, 2024, and healthy cash flows.
Management focuses on organic growth through capacity addition, technology, and new products without referring to external fundraising.
They continue to evaluate adjacencies and growth opportunities but have not disclosed any plans for raising funds via debt or equity.

Order book

Fenesta Building System has shown strong accretion in order booking as mentioned on page 7.
The business is expanding across geographies and SKUs despite the first quarter slowdown due to elections.
No specific numeric value for the current or expected order book or pending orders is disclosed in the transcript.
The general tone indicates a healthy pipeline of orders supporting growth momentum in the business segment.

See what DCM Shriram Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Commissioned 850 TPD caustic capacity in May 2024; capacity ramp-up will be gradual due to market oversupply.
120 MW captive power plant commissioned in June 2024, improving cost efficiency.
Hydrogen peroxide plant started trial runs; expected to be commissioned in Q2 FY25.
Epichlorohydrin plant trials to start in Q2 FY25; commercial production expected early Q3 FY25.
Actively working on starting activities on epoxy and other chlorine downstream products; board evaluation ongoing.
Evaluating additional chlorine downstream opportunities to increase captive chlorine consumption beyond current ~55%.
Focus on capacity, capability, technology, new products, and value addition as part of growth strategy.
Sustainability and cost-efficiency improvements integrated into operations and strategic pathways.

Track DCM Shriram Ltd — get its next earnings analysis in your feed

How does DCM Shriram Ltd rank vs peers in Diversified?

Pro feature

ThisDCM Shriram Ltd

Rev 3Mar 3

See where DCM Shriram Ltd sits in DiversifiedSee which companies these are, and every other name in the sector.Open rankings

How does DCM Shriram Ltd rank in Diversified?

Compare DCM Shriram Ltd against every Diversified company (Q1 FY25) on revenue, margins and earnings-call signals.

View Diversified leaderboard →

What DCM Shriram Ltd's management said in earlier quarters

Others in Diversified this season

Godrej Industries Ltd (Q4 FY25)
Q4 FY 2024-25 Total Income (Consolidated): ₹6,400 crore, up 25% YoY from ₹5,103 crore (Page 6). Key concall takeaways from Godrej Industries Ltd's Q4 FY25…
Godrej Industries Ltd (Q1 FY26)
Consolidated Total Income: ₹5,719 crore in Q1 FY26, up 9% YoY from ₹5,259 crore in Q1 FY25. Key concall takeaways from Godrej Industries Ltd's Q1 FY26 earnings…
Godrej Industries Ltd (Q2 FY26)
Consolidated Total Income:** ₹6,290 crore, up 23% YoY (Page 6) . Key concall takeaways from Godrej Industries Ltd's Q2 FY26 earnings call — and how it ranks…
Godrej Industries Ltd (Q3 FY26)
Consolidated sales revenue grew by 9% YoY in INR. Key concall takeaways from Godrej Industries Ltd's Q3 FY26 earnings call — and how it ranks against sector…

Compare:vs Godrej Industries Ltd vs 3M India Ltd vs TTK Healthcare

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

DCM Shriram Ltd Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does DCM Shriram Ltd rank in Diversified?

Continue your research

What DCM Shriram Ltd's management said in earlier quarters

Others in Diversified this season